Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.7047
+0.0337 (5.02%)
At close: Mar 26, 2026, 4:00 PM EDT
0.7000
-0.0047 (-0.67%)
After-hours: Mar 26, 2026, 4:10 PM EDT
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2024. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$35,720
Profits / Employee
-$1,574,946
Market Cap
8.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| Imunon | 25 |
| BiomX | 20 |
| Kiora Pharmaceuticals | 12 |
| TransCode Therapeutics | 7 |
| Alzamend Neuro | 6 |
| Pulmatrix | 2 |
| Addex Therapeutics | 2 |
APRE News
- 10 days ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
- 5 weeks ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - GlobeNewsWire
- 7 weeks ago - Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire